The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature
European Urology, 03/19/2012Sonpavde G et al.
The addition of sipuleucel–T, an immunotherapeutic agent, to the armamentarium represents a paradigm shift in therapy for metastatic castration–resistant prostate cancer. The rational combination and proper sequencing of sipuleucel–T with other newly approved agents and emerging agents will be important to evaluate.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.